The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
|Articles|April 22, 2022
Daily Medication Pearl: Pilocarpine (Vuity)
Author(s)Saro Arakelians, PharmD
Pilocarpine (Vuity) is a cholinergic muscarinic receptor agonist indicated for the treatment of presbyopia in adults.
Advertisement
Medication Pearl of the Day: Pilocarpine (Vuity)
Indication: Pilocarpine (Vuity) is a cholinergic muscarinic receptor agonist indicated for the treatment of presbyopia in adults.
Insight:
- Dosing:Instill 1 drop of Vuity in each eye once daily.
- Dosage forms: Ophthalmic solution containing pilocarpine hydrochloride 1.25%.
- Adverse events:Most common adverse reactions (>5%) are headache and conjunctival hyperemia.
- Mechanism of action: Pilocarpine hydrochloride is a cholinergic muscarinic agonist that activates muscarinic receptors located at smooth muscles, such as the iris sphincter muscle and ciliary muscle. Vuity contracts the iris sphincter muscle, constricting the pupil to improve near and intermediate visual acuity while maintaining some pupillary response to light. Vuity also contracts the ciliary muscle and may shift the eye to a more myopic state.
- Manufacturer: Allergan
Source:
Advertisement
Related to this article
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
Oncology Pharmacists Reduce Adverse Drug Reactions in Hematologic Cancer Care
4
What Pharmacists Should Know About Sea Buckthorn for Respiratory Health
5